Financial Performance - The net profit attributable to shareholders for the fiscal year 2024 is CNY 35,520,981.37, with a distributable profit of CNY 143,785,882.90 as of December 31, 2024[7]. - The proposed cash dividend is CNY 2.1 per 10 shares (including tax), which totals CNY 11,035,900.47, accounting for 31.07% of the net profit attributable to shareholders[8]. - The company's operating revenue for 2024 reached ¥502,828,582.77, representing a 9.78% increase compared to ¥458,027,970.99 in 2023[24]. - The net profit attributable to shareholders for 2024 was ¥35,520,981.37, a decrease of 23.98% from ¥46,723,751.80 in 2023[24]. - The net cash flow from operating activities significantly dropped by 82.89% to ¥9,845,141.88 in 2024, down from ¥57,544,460.40 in 2023[24]. - The company's total assets increased by 7.71% to ¥1,460,566,903.73 at the end of 2024, compared to ¥1,356,033,826.42 at the end of 2023[24]. - Basic earnings per share for 2024 were ¥0.6745, reflecting a decline of 28.54% from ¥0.9439 in 2023[25]. - The overall gross margin decreased by 3.53 percentage points compared to the previous year, mainly due to changes in product mix and rising fixed costs[122]. Research and Development - Research and development expenses accounted for 13.98% of operating revenue in 2024, a slight decrease from 14.66% in 2023[26]. - R&D investment reached 70.28 million RMB, a year-on-year increase of 4.67%, representing 13.98% of main business revenue, with 23 new invention patents applied for during the period[42]. - The company applied for 23 invention patents and 10 utility model patents during the reporting period, and obtained 31 invention patents and 11 utility model patents in 2024, totaling 75 invention patents and 119 utility model patents cumulatively[81]. - The company has developed core technologies in precision optical coating, high-precision optical polishing, high-precision optical bonding, optical lens and system design, and low-stress high-precision assembly, with significant advancements in each area[79]. - Total R&D expenditure increased by 4.67% to ¥70,278,349.52 compared to the previous year[84]. Market and Industry Trends - The global photonics market is projected to grow from approximately $92.06 billion in 2023 to about $164.26 billion by 2032, with a compound annual growth rate (CAGR) of around 6.7% from 2024 to 2032[57]. - The precision optical components market in medical and life sciences, industrial inspection, and aerospace is expected to increase from ¥19.8 billion in 2023 to ¥30.69 billion by 2027, with a CAGR of 11.6%[57]. - The global semiconductor manufacturing equipment sales are forecasted to reach $109 billion in 2024, representing a year-on-year growth of 3.4%[61]. - The AR and VR market is estimated to grow from $47.6 billion in 2023 to $210.4 billion by 2030, achieving a CAGR of 23.7%[66]. - The precision optical industry is critical for high-tech applications in sectors such as biomedical, artificial intelligence, and aerospace, driving the industry's growth[56]. Corporate Governance - The company has not reported any special arrangements for corporate governance[10]. - The company has strengthened its internal control system and governance structure to improve decision-making processes and enhance risk management[45]. - The board of directors will continue to play a core role in corporate governance, ensuring compliance with regulations and enhancing decision-making efficiency through independent directors and specialized committees[160]. - The company is committed to improving its governance structure in accordance with the Company Law and Securities Law of the People's Republic of China, ensuring effective operation of the shareholders' meeting, board of directors, and supervisory board[163]. - The company has successfully elected new members to its board of directors and supervisory board, ensuring a fresh perspective in governance[164]. Risk Management - The company has disclosed various risks it may face in its operations, which are detailed in the report[4]. - The company faces risks related to the customization of R&D not matching client needs, which could lead to customer loss and negatively impact revenue[96]. - The company is exposed to foreign exchange risks as a significant portion of sales is conducted in foreign currencies, particularly USD[107]. - The company's performance is influenced by macroeconomic conditions and market dynamics, with potential adverse effects from international trade instability[103]. Talent Development - The company emphasizes talent development and has implemented a strategy for talent acquisition and training to ensure a robust talent pipeline[43]. - The company focuses on talent development by optimizing internal training systems and providing quality training programs for employees at all levels[44]. - The company has a dual career development path for management and technical staff, focusing on the development of engineers and R&D personnel[195]. Production and Operations - The production model is based on a "make-to-order" principle, allowing the company to respond flexibly to market demands and customer needs[53]. - The company has developed advanced optical systems, including laser interference systems and 3D scanning modules, to meet the growing demands of the semiconductor and medical equipment sectors[50]. - The company is focusing on integrating advanced manufacturing technologies to enhance precision polishing and testing capabilities, crucial for various high-tech applications[72]. Financial Management - The company has approved the use of part of the raised funds to permanently supplement working capital, reflecting a strategic financial decision[165]. - The company has passed resolutions regarding the 2023 annual report, financial budget for 2024, and profit distribution plan, indicating a structured approach to financial management and shareholder engagement[164]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion in Q3 2023, representing a 15% year-over-year growth[171]. Shareholder Engagement - The company has approved a cash dividend of 6.5 RMB per 10 shares, totaling 34,320,000 RMB (including tax) for the 2023 fiscal year[197]. - Minority shareholders have had sufficient opportunities to express their opinions and their legal rights have been adequately protected[198].

证券代码：688502 证券简称：茂莱光学 公告编号：2025-015 南京茂莱光学科技股份有限公司 2024 年度业绩快报更正公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 南京茂莱光学科技股份有限公司（以下简称"公司"）董事会于 2025 年 2 月 28 日在《中国证券报》《上海证券报》《证券时报》《证券日报》《经济参 考报》和上海证券交易所网站（www.sse.com.cn）披露了公司《2024 年度业绩 快报公告》，现对相关内容修正如下，财务数据未经会计师事务所审计，具体以 公司披露的 2024 年年度报告为准，提请投资者注意投资风险。 一、修正前后的主要财务数据和指标 单位：万元 | 项目 | 本报告期 | | 上年同期 | 修正后的增减 | | --- | --- | --- | --- | --- | | | 修正前 | 修正后 | | 变动幅度（％） | | 营业总收入 | 52,283.40 | 50,282.86 | 45,802.80 | 9.78% | | 营业利润 | 4,811.04 | ...

企查查股权穿透显示，该公司由茂莱光学全资持股。 人民财讯3月17日电，企查查APP显示，近日，北京茂莱赋芯科技有限公司成立，法定代表人为范一， 注册资本50万元，经营范围包含：光学仪器销售；光学仪器制造；半导体器件专用设备销售；半导体器 件专用设备制造等。 ...

南京茂莱光学科技股份有限公司（以下简称"公司"）于 2024 年 4 月 26 日召开 第四届董事会第二次会议，审议通过了《关于使用超募资金以集中竞价交易方式 回购股份的议案》，同意公司使用部分超募资金以集中竞价交易方式回购公司已发 行的部分人民币普通股（A 股）股份，回购的股份将用于员工持股计划或股权激 励，并在回购完成后三年内予以转让。本次回购资金总额不低于人民币 2,500.00 万元（含），不超过人民币 5,000.00 万元（不含）；回购价格不高于第四届董事会 第二次会议审议通过回购决议前 30 个交易日公司股票交易均价的 150%；回购期 限为自第四届董事会第二次会议审议通过回购方案之日起 12 个月内。具体内容详 见公司分别于 2024 年 4 月 27 日、2024 年 5 月 15 日在上海证券交易所网站 （www.sse.com.cn）披露的《关于使用超募资金以集中竞价交易方式回购股份方案 的公告》、《关于使用超募资金以集中竞价交易方式回购股份的回购报告书》。 | 回购方案首次披露日 | 2024/4/27，由副董事长、总经理范一先生提议 | | --- | --- | | 回购方案实施期 ...

证券代码：688502 证券简称：茂莱光学 公告编号：2025-012 南京茂莱光学科技股份有限公司 首次公开发行战略配售限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 根据中国证券监督管理委员会于 2023 年 1 月 12 日出具的《关于同意南京茂 莱光学科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2023〕84 号）， 公司获准首次公开发行人民币普通股（A 股）13,200,000 股，并于 2023 年 3 月 9 日在上海证券交易所科创板上市。 公司首次公开发行股票完成后，总股本为 52,800,000 股，其中无限售条件流 通股为 12,061,430 股，有限售条件流通股为 40,738,570 股。 本次上市流通的限售股为公司首次公开发行战略配售限售股，限售股股东数 量为 1 名，限售期为自公司股票上市之日起 24 个月，该部分限售股股东对应的股 份数量为 573,723 股，占公司上市后股本总数的 1.0866%，前述具体情况详见公司 2023 年 3 月 ...

中国国际金融股份有限公司 关于南京茂莱光学科技股份有限公司 首次公开发行战略配售限售股上市流通的核查意见 中国国际金融股份有限公司（以下简称"保荐机构"）作为南京茂莱光学科 技股份有限公司（以下简称"茂莱光学"或"公司"）持续督导的保荐机构，根 据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市规则》 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》《上市公 司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上海证券交 易所上市公司自律监管指引第 7 号——回购股份》等有关规定，对公司首次公开 发行战略配售限售股上市流通事项进行了核查，具体情况如下： 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于2023年1月12日出具的《关于同意南京茂莱 光学科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2023〕84号）， 公司获准首次公开发行人民币普通股（A股）13,200,000股，并于2023年3月9日在 上海证券交易所科创板上市。 公司首次公开发行股票完成后，总股本为52,800,000股，其中无限售条件流 通股为12,061,430股，有限售条 ...

Financial Performance - The company achieved total operating revenue of 522.83 million yuan, a year-on-year increase of 14.15%[4] - The net profit attributable to the parent company was 42.19 million yuan, a decrease of 9.70% compared to the previous year[6] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 35.36 million yuan, an increase of 7.92% year-on-year[6] - The basic earnings per share decreased by 15.12% to 0.8012 yuan[4] - The weighted average return on net assets decreased by 1.20 percentage points to 3.58%[4] Assets and Equity - Total assets at the end of the reporting period were 1,469.36 million yuan, reflecting an 8.36% year-on-year growth[6] - The company's equity attributable to the parent company was 1,178.40 million yuan, a decrease of 1.05% from the previous year[6] Investments and Growth Drivers - The company increased its R&D and market expansion investments, leading to higher sales and R&D expenses[6] - Revenue growth was primarily driven by the semiconductor sector and significant growth in the autonomous driving sector[6] Challenges - The company faced short-term impacts from product iterations of major clients in the life sciences sector, affecting revenue growth expectations[6]

一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 2 月 13 日 （二） 股东大会召开的地点：江苏省南京市江宁开发区铺岗街 398 号会议室 证券代码：688502 证券简称：茂莱光学 公告编号：2025-011 南京茂莱光学科技股份有限公司 2025 年第一次临时股东会决议公告 本次会议是否有被否决议案：无 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 34 | | --- | --- | | 普通股股东人数 | 34 | | 2、出席会议的股东所持有的表决权数量 | 33,230,293 | | 普通股股东所持有表决权数量 | 33,230,293 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例 | 63.2332 | | （%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 63.2332 | （四） ...

国浩律师(南京)事务所 股东会法律意见书 国浩律师(南京) 事务所 关于南京茂莱光学科技股份有限公司 2025 年第一次临时股东会之 法律意见书 致:南京茂莱光学科技股份有限公司 根据《中华人民共和国证券法》《中华人民共和国公司法》以及中国证券监 督管理委员会《上市公司股东大会规则》的规定,本所接受南京茂莱光学科技股 份有限公司(以下简称"公司")的聘请,指派王卓、高林律师出席公司 2025 年第一次临时股东会(以下简称"本次股东会"),并就公司本次股东会出具法 律意见书。 为出具本法律意见书,本所律师参加了公司本次股东会,并对本次股东会召 集和召开的相关事实以及公司提供的文件进行了核查和验证。 1 国浩律师(南京)事务所 股东会法律意见书 共 2 名，持有公司有表决权股份 33,200,000 股，占公司总股本的 62.8788%。 3、根据上证所信息网络有限公司向公司提供的信息资料,在 2025年 2 月 13 日 9:15-9:25、9:30--11:30 和 13:00--15:00 网络投票时间内通过上海证券交 易所交易系统进行网络投票的股东以及在 2025年 2 月 13 日 9:15-15:00 ...

证券代码：688502 证券简称：茂莱光学 公告编号：2025-010 南京茂莱光学科技股份有限公司 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司在回购股份期间应于每个月的前三个交易日 内披露截至上月末的回购进展情况。现将公司回购股份进展情况公告如下： 截至 2025 年 1 月 31 日，公司通过集中竞价交易方式已累计回购股份 248,093 股，占公司总股本 52,800,000 股的 0.4699%，回购成交的最高价为 118.80 元/股， 最低价为 71.01 元/股，支付的资金总额为人民币 26,923,480.72 元（不含印花税、 交易佣金等交易费用）。 本次回购股份符合相关法律法规、规范性文件的规定及公司回购股份方案。 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/4/27，由副董事长、总经理范一先生提议 | | --- | --- | | 回购方案实施期限 | 待第四届董 ...